PREVAIL is a Phase 3 study evaluating the safety and effectiveness of an investigational oral medication (obicetrapib) designed to reduce low-density lipoprotein cholesterol (LDL-C) and the risk of major adverse cardiovascular event(s) (MACE). 

Key eligibility criteria 

• ≥18 years of age 
• History of atherosclerotic cardiovascular disease (ASCVD) 
• Has 1 of the fasting serum LDL-C criteria: 
• Fasting serum LDL-C ≥80 mg/dL (2.1 mmol/L) and <100 mg/dL (2.6 mmol/L) with at least 1 of the following risk enhancers: 
• Recent myocardial infarction (MI) (>3 and <12 months prior to Randomisation); 
• Type 2 diabetes mellitus; 
• Fasting TG >150 mg/dL (>1.7 mmol/L); and/or 
• Fasting HDL-C <40 mg/dL (<1.0 mmol/L) 

      OR 

• Fasting serum LDL-C ≥100 mg/dL (2.6 mmol/L) 
• Taking a maximally tolerated lipid-modifying therapy, including statin therapy (e.g., atorvastatin or rosuvastatin), ezetimibe, bempedoic acid, PCSK9-targeted therapies, and fibrates. Patients taking low dose or no statin therapy due to statin intolerance and/or patients taking a combination of therapies may be eligible. 

For more information, please contact our reception team on 01752 346634, or email the practice and we will arrange an appointment with our Research team.